Here are the Genetic variations in anti-diabetic drug targets and COPD risk: evidence from mendelian randomization journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Genetic variations, newer anti diabetic drugs, genetic variation in a population, genetic variation in mitosis, anti diabetic drugs pharmacology, genetics and type 2 diabetes, genetic variation in natural selection video, genetic variations meaning, genetic variation in sexual reproduction.
Genetic variations in anti-diabetic drug targets and COPD risk: evidence from mendelian randomization
Background: Previous research has emphasized the potential benefits of anti-diabetic medications in inhibiting the exacerbation of Chronic Obstructive Pulmonary Disease (COPD), yet the role of anti-diabetic drugs on COPD risk remains uncertain.
Methods: This study employed a Mendelian randomization (MR) approach to evaluate the causal association of genetic variations related to six classes of anti-diabetic drug targets with COPD. The primary outcome for COPD was obtained from the Global Biobank Meta-analysis Initiative (GBMI) consortium, encompassing a meta-analysis of 12 cohorts with 81,568 cases and 1,310,798 controls. Summary-level data for HbA1c was derived from the UK Biobank, involving 344,182 individuals. Positive control analysis was conducted for Type 2 Diabetes Mellitus (T2DM) to validate the choice of instrumental variables. The study applied Summary-data-based MR (SMR) and two-sample MR for effect estimation and fur ther adopted colocalization analysis to verify evidence of genetic variations.
Results: SMR analysis revealed that elevated KCNJ11 gene expression levels in blood correlated with reduced COPD risk (OR = 0.87, 95% CI = 0.79–0.95; p = 0.002), whereas an increase in DPP4 expression corresponded with an increased COPD incidence (OR = 1.18, 95% CI = 1.03–1.35; p = 0.022). Additionally, the primary method within MR analysis demonstrated a positive correlation between PPARG-mediated HbA1c and both FEV1 (OR = 1.07, 95% CI = 1.02–1.13; P = 0.013) and FEV1/FVC (OR = 1.08, 95% CI = 1.01–1.14; P = 0.007), and a negative association between SLC5A2-mediated HbA1c and FEV1/FVC (OR = 0.86, 95% CI = 0.74–1.00; P = 0.045). No colocalization evidence with outcome phenotypes was detected (all PP.H4 < 0.7).
Conclusion: This study provides suggestive evidence for anti-diabetic medications' role in improving COPD and lung function. Further updated MR analyses are warranted in the future, following the acquisition of more extensive and comprehensive data, to validate our results. © The Author(s) 2024.
Authors : Su Y.; Zhang Y.; Xu J.
Source : BioMed Central Ltd
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1186/s12890-024-02959-1 |
| ISSN | 14712466 |
| Volume | 24 |
You can download the article here
If You have any problem, contact us here